Adamax: The Modified Semax Analog and Its Thin Evidence Base
A synthetic nonapeptide analog of Semax with N-terminal acetylation and adamantyl C-terminal modification, studied for enhanced BDNF signaling and blood-brain barrier penetration.
What is Adamax?
Adamax (N-Acetyl Semax Adamantyl, Ac-MEHFPGPAG-NH₂) is a structurally engineered 9-amino-acid peptide derived from Semax, itself an analog of the ACTH(4-10) fragment. The adamantane group at the C-terminus is investigated for enhanced blood-brain barrier penetration and enzymatic stability relative to the parent Semax compound. The N-terminal acetyl group provides additional resistance to aminopeptidase degradation. Research — primarily derived from the parent Semax compound — shows modulation of BDNF expression and TrkB receptor phosphorylation in hippocampal models. No human clinical trial data exists; all evidence is preclinical.
Quick facts
- Storage
- Store the lyophilized vial refrigerated (2-8°C) or at -20°C, away from light. Once reconstituted, keep refrigerated at 2-8°C and use promptly.
Dosing at a glance
10mg vial + 2mL bacteriostatic water = 5000mcg/mL. A 500mcg dose is 0.1mL (10 units on an insulin syringe). Run the numbers in the reconstitution calculator.
Doses shown are those reported in published research, not a recommendation.
Adamax Mechanism of Action
BDNF Upregulation and TrkB Receptor Activation
Adamax is structurally derived from Semax, a heptapeptide analog of the ACTH(4-10) fragment. Its primary mechanism of interest involves the modulation of brain-derived neurotrophic factor (BDNF) expression and activation of its primary receptor, TrkB. In rodent hippocampal models, Semax administration at 50 μg/kg produced a 1.4-fold increase in BDNF protein levels and a 1.6-fold increase in TrkB tyrosine phosphorylation. Adamax is investigated within this same experimental framework to assess whether the adamantyl modification prolongs or enhances these interactions through greater enzymatic stability.
Adamantyl Modification and Blood-Brain Barrier Penetration
The defining structural feature of Adamax relative to standard Semax is the adamantyl group at the C-terminus, derived from Peptide P21. Adamantane is a lipophilic, cage-like hydrocarbon structure that is hypothesized to enhance blood-brain barrier penetration by increasing lipophilicity and reducing polar surface area. The N-terminal acetyl group provides complementary protection against aminopeptidase enzymatic degradation, extending the in vivo half-life relative to unmodified Semax. Together these two modifications are the focus of Adamax preclinical research — they are not properties confirmed in human trials.
Downstream Signaling: MAPK/ERK and PI3K/Akt
Semax-derived peptides engage downstream intracellular cascades following TrkB receptor activation. In cell-based experimental systems, MAPK/ERK and PI3K/Akt signaling pathways are engaged — both associated with neuronal survival, protein synthesis, and synaptic remodeling. Additionally, the HGF/c-Met pathway has been implicated in Adamax-class compound research in the context of synaptogenesis and dendritic spine formation in APP/PS1 transgenic mouse models. These findings are preclinical and not consistent across all model systems.
Adamax Dosage and Protocols
Dose Ranges and Protocol
No established clinical dosing protocol exists for Adamax. Extrapolating from Semax research, doses of 300–600 mcg once or twice daily via intranasal or subcutaneous administration are the most commonly reported research parameters. Intranasal delivery is the traditional route for Semax-class analogs due to proximity to the olfactory bulb and direct CNS access, though subcutaneous injection is also used in research settings. All dosing information is extrapolated from preclinical research on Semax analogs — no formal human dose-finding study has been conducted for Adamax.
Reconstitution
Adamax ships as a lyophilized powder. A common starting point is a 10 mg vial reconstituted with 2 mL bacteriostatic water, yielding 5,000 mcg/mL. A 500 mcg dose equals 0.1 mL (10 units on an insulin syringe). Add the water slowly down the vial wall, swirl gently (do not shake), and allow full dissolution. Reconstituted peptide should be refrigerated at 4°C and used within 7 days. Lyophilized powder is stable for ≥24 months when stored at −20°C protected from light and moisture.
Adamax Side Effects and Safety
Known and Theoretical Risks
No formal human safety or tolerability data exists for Adamax. Theoretical concerns center on the adamantyl modification — a lipophilic adamantane group specifically investigated for enhanced blood-brain barrier penetration, meaning uncontrolled exposure carries uncharacterized risks of CNS delivery. Reported effects extrapolated from Semax-class compounds include transient headache, nasal irritation (intranasal route), light-headedness, and mild stimulatory effects. Active psychiatric conditions, pregnancy, and known CNS disorders are considered contraindications without physician oversight.
Handling Precautions
Lyophilized Adamax powder presents an inhalation hazard during weighing and reconstitution. All handling should be performed in a certified fume hood or biosafety cabinet with N95 respiratory protection, nitrile gloves, lab coat, and safety eyewear. Direct skin and eye contact must be avoided. Because the adamantane group is investigated for enhanced BBB penetration, any accidental mucosal or dermal exposure should be treated as a potential pharmacological event and managed per institutional protocols.
Adamax Research Evidence
Parent Compound Evidence: Semax
Direct clinical data on Adamax does not exist — all human inference is extrapolated from the parent Semax compound. Semax was shown to bind specifically to membrane-associated sites in rat basal forebrain with a dissociation constant of 2.4 ± 1.0 nM. A single intranasal application at 50 μg/kg produced rapid increases in BDNF protein levels in the basal forebrain, alongside ~3-fold increases in exon III BDNF mRNA and ~2-fold increases in TrkB mRNA. Treated animals showed increased conditioned avoidance reactions. Adamax is studied within this framework to assess how the adamantyl modification alters these neurotrophin interactions. [Dolotov et al., 2006]
Regulatory and Legal Status
Adamax has no FDA-approved indication and is not approved for human use. It is sold exclusively as a research-grade compound. Notably, Adamax has been intercepted at the border as an unapproved designer peptide in New Zealand. In June 2025, New Zealand's Medicines Classification Committee received a submission recommending Adamax be classified as a prescription medicine. Researchers and users should verify the legal status in their jurisdiction prior to purchase or use. It is not listed on the WADA 2026 Prohibited List, but competitive athletes should verify via GlobalDRO.com before any research use.
Research Limitations
All mechanistic data for Adamax is derived from preclinical animal studies, primarily on the parent Semax compound rather than Adamax itself. No randomized controlled trial, phase 1 clinical trial, or published human pharmacokinetic data exists for Adamax as of mid-2026. The adamantane modification's actual effect on blood-brain barrier penetration in humans remains unconfirmed. The compound's effects, safety profile, and long-term consequences in humans are entirely unknown. This is educational information, not medical advice.
Adamax Stacking and Combinations
Adamax + Selank
A common research pairing for cognitive and anxiolytic effects. Semax-class compounds (including Adamax) target BDNF/TrkB upregulation and cognitive enhancement, while Selank (a tuftsin analog) has been associated with anxiolytic effects and modulation of GABAergic and serotonergic systems. The two compounds operate through distinct mechanisms, and their combination is used in nootropic research to target both cognitive performance and stress-response systems simultaneously. No formal clinical trial data exists for this combination.
Adamax + Semax
Some researchers combine Adamax with standard Semax to compare the effect of the adamantyl modification directly. This pairing functions more as a research construct than a practical protocol, as both target identical upstream systems (BDNF/TrkB) through closely related mechanisms. There is no documented synergistic benefit to combining them, and dosing math becomes complex. For practical cognitive support protocols, one or the other is typically selected based on the desired stability and blood-brain barrier penetration profile.
Adamax Pharmacokinetics
Half-Life and Stability
No formal pharmacokinetic study has been published for Adamax in humans or animals. Estimated half-life is approximately 2–4 hours based on Semax analog data, though the N-terminal acetyl group and adamantyl modification are specifically designed to extend enzymatic stability relative to native Semax. The acetyl group protects against aminopeptidase degradation; the adamantane group is hypothesized to reduce renal clearance through its lipophilic cage structure. These are mechanistic hypotheses, not confirmed human PK data.
Administration Routes and Absorption
Adamax is administered by intranasal spray or subcutaneous injection in research settings. The intranasal route is preferred for Semax-class analogs because it bypasses the blood-brain barrier via the olfactory epithelium and trigeminal nerve pathways, delivering compound directly to CNS tissue. However, the adamantane modification's enhanced blood-brain barrier penetration profile may make systemic subcutaneous dosing equally viable in preclinical models. Absorption kinetics, bioavailability, and Tmax values have not been formally published for Adamax as a standalone compound.
Contraindications
- active psychiatric conditions
- pregnancy
- known CNS disorders without physician oversight
Frequently asked questions
What is a typical Adamax dose?
Published research protocols report 300–600 mcg, 1-2x daily. This is the range described in the literature, not a recommendation.
What is the half-life of Adamax?
~2–4 hours (estimated, based on Semax analog data).
Is Adamax backed by strong evidence?
Adamax carries a REGEN research grade of F. REGEN Research Tier F — no published human trials — sold as a research chemical.
How is Adamax administered?
Routes reported in the literature: intranasal, subcutaneous.
Who should avoid Adamax?
Contraindications noted in the literature include active psychiatric conditions, pregnancy, known CNS disorders without physician oversight.